Cheryl A Chessick et al. (2006). «Azapirones for generalized anxiety disorder». Cochrane Depression, Anxiety and Neurosis Group. doi:10.1002/14651858.CD006115. Consultado el 22 de julio de 2015. «Las azapironas parecían ser útiles en el tratamiento de TAG, en particular para los participantes que no habían tomado BZD. Es posible que las azapironas no sean superiores a las benzodiazepinas y parecen no ser tan aceptables como las benzodiazepinas. Los efectos secundarios parecieron ser leves y no graves en el grupo tratado con azapirona. Se necesitan estudios a más largo plazo para demostrar que las azapironas son eficaces en el tratamiento del TAG, una enfermedad crónica a largo plazo.»
Pinna G, Galici R, Schneider HH, Stephens DN, Turski L (Mar 1997). «Alprazolam dependence prevented by substituting with the beta-carboline abecarnil». Proceedings of the National Academy of Sciences of the United States of America94 (6): 2719-23. doi:10.1073/pnas.94.6.2719.
Giuseppe Guaiana1, Corrado Barbui, Andrea Cipriani (8 de diciembre de 2010). «Hydroxyzine for generalised anxiety disorder». The Cochrane Library. Cochrane Depression, Anxiety and Neurosis Group. doi:10.1002/14651858.CD006815.pub2.
Fuxe K, Agnati LF, Ungerstedt U (enero de 1976). «The effect of mepiprazole on central monoamine neurons. Evidence for increased 5-hydroxytryptamine and dopamine receptor activity». European Journal of Pharmacology35 (1): 93-108. PMID943291. doi:10.1016/0014-2999(76)90304-6.
Nobukazu Kakui et al. (mayo de 2009). «Anxiolytic-like profile of mirtazapine in rat conditioned fear stress model: Functional significance of 5-hydroxytryptamine 1A receptor and α1-adrenergic receptor». Pharmacology Biochemistry and Behavior92 (3): 393-398. doi:10.1016/j.pbb.2008.12.022.
G. A. Kennett (junio de 1992,). 5-HT1C receptor antagonists have anxiolytic-like actions in the rat social interaction model107 (2-3,). pp. 379-384. doi:10.1007/BF02245165.
D. Benjamin (1992). «Mianserin-induced 5-HT2 receptor downregulation results in anxiolytic effects in the elevated plus-maze test». Drug Development Research26 (3): 287-297. doi:10.1002/ddr.430260308.
Müller WE, Siebert B, Holoubek G, Gentsch C (noviembre de 2004). «Neuropharmacology of the anxiolytic drug opipramol, a sigma site ligand». Pharmacopsychiatry37 (Suppl 3): S189-197. PMID15547785. doi:10.1055/s-2004-832677.
Dr Siegfried Kasper, Bruce S. McEwen (enero de 2008). Neurobiological and Clinical Effects of the Antidepressant Tianeptine22 (1). pp. 15-26. doi:10.2165/00023210-200822010-00002.
Schruers, K; Griez, E (diciembre de 2004). «The effects of tianeptine or paroxetine on 35% CO2 provoked panic in panic disorder». Journal of Psychopharmacology18 (4): 553-8. PMID15582922. doi:10.1177/0269881104047283.
Uzbay, TI (mayo de 2008). «Tianeptine: potential influences on neuroplasticity and novel pharmacological effects». Progress in Neuro-psychopharmacology & Biological Psychiatry32 (4): 915-24. PMID17826881. doi:10.1016/j.pnpbp.2007.08.007.
Millan MJ, Brocco M, Gobert A, Dekeyne A (febrero de 2005). «Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade». Psychopharmacology (Berl.)177 (4): 448-58. PMID15289999. doi:10.1007/s00213-004-1962-z.
De Berardis, D; Serroni, N; Campanella, D; Olivieri, L; Moschetta, FS; Conti, CM; Conti, P; Di Giannantonio, M (abril de 2012). «A case of obsessive-compulsive disorder successfully treated with agomelatine monotherapy». Journal of Clinical Psychopharmacology32 (2): 289-290. PMID22388158. doi:10.1097/JCP.0b013e318249298c.
Bhutada, P; Dixit, P; Thakur, K; Deshmukh, P; Kaulaskar, S (julio de 2013). «Effects of agomelatine in a murine model of obsessive–compulsive disorder: Interaction with meta-chlorophenylpiperazine, bicuculline, and diazepam». The Kaohsiung Journal of Medical Sciences29 (7): 362-367. PMID23768699. doi:10.1016/j.kjms.2012.11.003.
Crippa, JA; Hallak, JE; Zuardi, AW; Chagas, MH; Quevedo, J; Nardi, AE (octubre de 2010). «Agomelatine in the treatment of social anxiety disorder». Progress in Neuro-Psychopharmacology and Biological Psychiatry34 (7): 1357-1358. PMID20637821. doi:10.1016/j.pnpbp.2010.07.007.
Jean-Philippe Guilloux et al. (octubre de 2013). «Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice». Neuropharmacology73: 147-159. doi:10.1016/j.neuropharm.2013.05.014.
Anthony J. Rothschild et al. (diciembre de 2012). «Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States». European Neuropsychopharmacology22 (12,): 858-866. doi:10.1016/j.euroneuro.2012.07.011.
Lee A. Dawson and Jeannette M. Watson (junio de 2009). Vilazodone: A 5-HT1A Receptor Agonist/Serotonin Transporter Inhibitor for the Treatment of Affective Disorders CNS Neuroscience & Therapeutics15 (2). pp. 107-117. doi:10.1111/j.1755-5949.2008.00067.x.
van der Kolk, BA (septiembre–octubre de 1987). «The drug treatment of post-traumatic stress disorder.». Journal of Affective Disorders13 (2): 203-13. PMID2960712. doi:10.1016/0165-0327(87)90024-3.
Southwick, SM; Bremner, JD; Rasmusson, A; Morgan CA, 3rd; Arnsten, A; Charney, DS (noviembre de 1999). «Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder.». Biological Psychiatry46 (9): 1192-204. PMID10560025. doi:10.1016/S0006-3223(99)00219-X.
Strawn, JR; Geracioti, TD, Jr (2008). «Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder.». Depression and Anxiety25 (3): 260-71. PMID17354267. doi:10.1002/da.20292.
Boehnlein, JK; Kinzie, JD (marzo de 2007). «Pharmacologic reduction of CNS noradrenergic activity in PTSD: the case for clonidine and prazosin.». Journal of Psychiatric Practice13 (2): 72-8. PMID17414682. doi:10.1097/01.pra.0000265763.79753.c1.
Najjar, F; Weller, RA; Weisbrot, J; Weller, EB (abril de 2008). «Post-traumatic stress disorder and its treatment in children and adolescents.». Current Psychiatry Reports10 (2): 104-8. PMID18474199. doi:10.1007/s11920-008-0019-0.
Neylan,, T.; Lenoci, M. & Samuelson, K. (2006), «No Improvement of Posttraumatic Stress Disorder Symptoms With Guanfacine Treatment», American Journal of Psychiatry163 (12): 2186-2188, PMID17151174, doi:10.1176/appi.ajp.163.12.2186.
Cheryl A Chessick et al. (2006). «Azapirones for generalized anxiety disorder». Cochrane Depression, Anxiety and Neurosis Group. doi:10.1002/14651858.CD006115. Consultado el 22 de julio de 2015. «Las azapironas parecían ser útiles en el tratamiento de TAG, en particular para los participantes que no habían tomado BZD. Es posible que las azapironas no sean superiores a las benzodiazepinas y parecen no ser tan aceptables como las benzodiazepinas. Los efectos secundarios parecieron ser leves y no graves en el grupo tratado con azapirona. Se necesitan estudios a más largo plazo para demostrar que las azapironas son eficaces en el tratamiento del TAG, una enfermedad crónica a largo plazo.»
Kennett GA, Dourish CT, Curzon G (1987). «Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression». Eur J Pharmacol.134 (3): 265-74. PMID2883013. doi:10.1016/0014-2999(87)90357-8.
Blanchard JC; Julou L. (marzo de 1983). «Suriclone: a new cyclopyrrolone derivative recognizing receptors labeled by benzodiazepines in rat hippocampus and cerebellum.». J Neurochem.40 (3): 601-7. PMID6298365. doi:10.1111/j.1471-4159.1983.tb08023.x.
Bandelow, B.; Wedekind, D.; León, T. (Jul 2007). «Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention». Expert Rev Neurother7 (7): 769-81. PMID17610384. doi:10.1586/14737175.7.7.769.
Owen, RT. (Sep 2007). «Pregabalin: its efficacy, safety and tolerability profile in generalized anxiety». Drugs Today (Barc)43 (9): 601-10. PMID17940637. doi:10.1358/dot.2007.43.9.1133188.
«D-cycloserine injected into the dorsolateral periaqueductal gray induces anxiolytic-like effects in rats». Behav Brain Res1: 271-374. 2014. doi:10.1016/j.bbr.2014.06.009.
Ren, Jintao; Xiaobai Li; Xinxin Zhang; Min Li; Yan Wang; Yuchao Ma (julio de 2013). «The effects of intra-hippocampal microinfusion of d-cycloserine on fear extinction, and the expression of NMDA receptor subunit NR2B and neurogenesis in the hippocampus in rats». Progress In Neuro-Psychopharmacology And Biological Psychiatry44: 257-264. PMID23523746. doi:10.1016/j.pnpbp.2013.02.017.
Baker, Kathryn; Gavan P. McNally; Rick Richardson (octubre de 2012). «D-cycloserine does not facilitate fear extinction by reducing conditioned stimulus processing or promoting conditioned inhibition to contextual cues». Learning & Memory19 (10): 461-469. PMID22984284. doi:10.1101/lm.026674.112.
Seredenin, SB; Antipova, TA; Voronin, MV; Kurchashova, SY; Kuimov, AN (2009). «Interaction of afobazole with sigma1-receptors». Bulletin of experimental biology and medicine148 (1): 42-4. PMID19902093. doi:10.1007/s10517-009-0624-x.
Val'Dman, A. V.; Zaikonnikova, I. V.; Kozlovskaya, M. M.; Zimakova, I. E. (1980). «A study of the spectrum of psychotropic action of mebicar». Bulletin of Experimental Biology and Medicine89 (5): 621. doi:10.1007/BF00835799.
Malykh AG; Sadaie MR (Feb 2010). «Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.». Drugs.70 (3): 287-312. PMID20166767. doi:10.2165/11319230-000000000-00000.
I. N. Nikol’skaya et al. (agosto de 2009,). «Clinical Effects of Anxiolytic Preparation Tenoten in Complex Therapy of Essential Hypertension». Bulletin of Experimental Biology and Medicine148 (2): 346-348. doi:10.1007/s10517-009-0683-z.
Sarris J, McIntyre E, Camfield DA. (abril de 2013). «Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence». CNS Drugs27 (4): 301-19. doi:10.1007/s40263-013-0059-9.
Irinéia Paulina Baretta et al. (marzo de 2012). «Anxiolytic-like effects of acute and chronic treatment with Achillea millefolium L. extract». Journal of Ethnopharmacology140 (1): 46-54. doi:10.1016/j.jep.2011.11.047.
Jerome Sarris et al. (diciembre de 2011). «Herbal medicine for depression, anxiety and insomnia: A review of psychopharmacology and clinical evidence». European Neuropsychopharmacology21 (12): 841-860. doi:10.1016/j.euroneuro.2011.04.002.
I. Nehdi (enero de 2011). «Characteristics, chemical composition and utilisation of Albizia julibrissin seed oil». Industrial Crops and Products33 (1): 30-34. doi:10.1016/j.indcrop.2010.08.004.
Judith Singhuber et al. (febrero de 2012). «GABAA receptor modulators from Chinese herbal medicines traditionally applied against insomnia and anxiety». Phytomedicine19 (3-4): 334-340. doi:10.1016/j.phymed.2011.10.009.
M.C. Hellión-Ibarrola et al. (mayo de 2016). «The anxiolytic-like effects of Aloysia polystachya (Griseb.) Moldenke (Verbenaceae) in mice». Journal of Ethnopharmacology105 (3): 400-408. doi:10.1016/j.jep.2005.11.013.
Wenyan Xie et al. (2012). «Botany, traditional uses, phytochemistry and pharmacology of Apocynum venetum L. (Luobuma): A review». Journal of Ethnopharmacology141 (1): 1-8. doi:10.1016/j.jep.2012.02.003.
Veronika BUTTERWECK et al. (2001). «Antidepressant Effects of Apocynum venetum Leaves in a Forced Swimming Test». Biological and Pharmaceutical Bulletin24 (7): 848-851. doi:10.1248/bpb.24.848.
Meizhu Zheng et al. (enero de 2012). «Antidepressant-like effect of hyperoside isolated from Apocynum venetum leaves: Possible cellular mechanisms». Phytomedicine19 (2): 145-149. doi:10.1016/j.phymed.2011.06.029.
Oliver Grundmann et al. (abril de 2009). «Kaempferol from the leaves of Apocynum venetum possesses anxiolytic activities in the elevated plus maze test in mice». Phytomedicine16 (4): 295-302. doi:10.1016/j.phymed.2008.12.020.
Oliver Grundmann et al. (abril de 2007). «Anti-anxiety effects of Apocynum venetum L. in the elevated plus maze test». Journal of Ethnopharmacology110 (3): 406-411. doi:10.1016/j.jep.2006.09.035.
C. López-Rubalcava et al. (enero de 2006). «Anxiolytic-like actions of the hexane extract from leaves of Annona cherimolia in two anxiety paradigms: Possible involvement of the GABA/benzodiazepine receptor complex». Life Sciences78 (7): 730-737. doi:10.1016/j.lfs.2005.05.078.
Sarris J et al. (2012). «Complementary medicine, exercise, meditation, diet, and lifestyle modification for anxiety disorders: a review of current evidence». Evid Based Complement Alternat Med. PMID22969831. doi:10.1155/2012/809653.
A. Moussaieff et al. (2008). «Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain». The Journal of The Federation of American Societies for Experimental Biology22 (8): 3024-3034. PMID18492727. doi:10.1096/fj.07-101865.
Danielle M. Strebel et al. (2014). «Anxiolytic and anti-depressant effects of Boswellia extract on CD1 Mus musculus». BIOS85 (2): 79-85. doi:10.1893/0005-3155-85.2.79.
Arieh Moussaieff et al. (septiembre de 2012,). «Incensole acetate reduces depressive-like behavior and modulates hippocampal BDNF and CRF expression of submissive animals». Journal of Psychopharmacology. doi:10.1177/0269881112458729.
M Molina-Hernández et al. (julio de 2004). «Anxiolytic-like actions of leaves of Casimiroa edulis (Rutaceae) in male Wistar rats». Journal of Ethnopharmacology93 (1): 93-98. doi:10.1016/j.jep.2004.03.039.
S. Mora et al. (febrero de 2005). «Central nervous system activity of the hydroalcoholic extract of Casimiroa edulis in rats and mice». Journal of Ethnopharmacology97 (2): 191-197. doi:10.1016/j.jep.2004.10.028.
A.W. Zuardi et al. (abril de 2006). «Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug». Braz J Med Biol Res39 (4): 421-429. doi:10.1590/S0100-879X2006000400001.
Bergamaschi MM et al. (mayo de 2011). «Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients». Neuropsychopharmacology36 (6): 1219-26. doi:10.1038/npp.2011.6.
Crippa JA et al. (enero de 2011). «Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report». J Psychopharmacol25 (1): 121-30. doi:10.1177/0269881110379283.
F.F. Rochaa et al. (enero-febrero de 2002). «Evaluation of the anxiolytic-like effects of Cecropia glazioui Sneth in mice». Pharmacology Biochemistry and Behavior71 (1-2): 183-190. doi:10.1016/S0091-3057(01)00695-5.
F.F. Rochaa et al. (junio de 2007). «Antidepressant-like effect of Cecropia glazioui Sneth and its constituents – In vivo and in vitro characterization of the underlying mechanism». Phytomedicine14 (6): 396-402. doi:10.1016/j.phymed.2007.03.011.
Maria Isabel Roth Carvalho-Freitas; Mirtes Costa (2002). «Anxiolytic and Sedative Effects of Extracts and Essential Oil from Citrus aurantium L.». Biological and Pharmaceutical Bulletin25 (12): 1629-1633. doi:10.1248/bpb.25.1629.
Aline de Moraes Pultrini, Luciane Almeida Galindo, Mirtes Costa (marzo de 2006). «Effects of the essential oil from Citrus aurantium L. in experimental anxiety models in mice». Life Sciences78 (15): 1720-1725. doi:10.1016/j.lfs.2005.08.004.
Celso A R A Costa et al. (2013). «Citrus aurantium L. essential oil exhibits anxiolytic-like activity mediated by 5-HT1A-receptors and reduces cholesterol after repeated oral treatment». BMC Complementary and Alternative Medicine13 (1). doi:10.1186/1472-6882-13-42.
Rahnama, S. et al. (abril de 2015). «Anti-amnesic activity of Citrus aurantium flowers extract against scopolamine-induced memory impairments in rats». Neurological Sciences36 (4): 553-560. doi:10.1007/s10072-014-1991-2.
Koulivand, PH; Khaleghi, Ghadiri M; Gorji, A (2013). «Lavender and the nervous system». Evidence-based complementary and alternative medicine: eCAM.2013: 681304. PMID23573142. doi:10.1155/2013/681304.
Pittler MH, Ernst E (2000). «Efficacy of kava extract for treating anxiety: systematic review and meta-analysis». J Clin Psychopharmacol20: 84. doi:10.1097/00004714-200002000-00014.
Volz HP, Kieser M (1997). «Kava-kava extract WS 1490 versus placebo in anxiety disorders--a randomized placebo-controlled 25-week outpatient trial». Pharmacopsychiatry30: 1-5. doi:10.1055/s-2007-979474.
Max H Pittler, Edzard Ernst (2003). «Kava extract versus placebo for treating anxiety». Cochrane Database Syst Rev. PMID12535473. doi:10.1002/14651858.CD003383.
Maribel Herrera-Ruiz et al. (2006). «Antidepressant and anxiolytic effects of hydroalcoholic extract from Salvia elegans». Journal of Ethnopharmacology107 (1): 53-58. doi:10.1016/j.jep.2006.02.003.
David O Kennedy et al. (octubre de 2005). «Effects of Cholinesterase Inhibiting Sage (Salvia officinalis) on Mood, Anxiety and Performance on a Psychological Stressor Battery». Neuropsychopharmacology31: 845-852. doi:10.1038/sj.npp.1300907.
Lincoln Sakiara Miyasaka, Álvaro N Atallah, Bernardo Soares (18 de octubre de 2006). «Valerian for anxiety disorders». The Cochrane Library. doi:10.1002/14651858.CD004515.pub2.
Dietmar Benke et al. (enero de 2009). «GABAA receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts». Neuropharmacology56 (1): 174-181. doi:10.1016/j.neuropharm.2008.06.013.
S. Khom et al. (julio de 2007). «Valerenic acid potentiates and inhibits GABAA receptors: Molecular mechanism and subunit specificity». Neuropharmacology53 (1): 178-187. doi:10.1016/j.neuropharm.2007.04.018.
Shephard RA (junio de 1987). «Behavioral effects of GABA agonists in relation to anxiety and benzodiazepine action». Life Sci.40 (25): 2429-36. PMID2884549. doi:10.1016/0024-3205(87)90758-2.
Kokila, K. (2013). «Copia archivada». Int J Pharm Pharm Sci,. 5 Suppl. 3: 70-73. Archivado desde el original el 24 de septiembre de 2015. Consultado el 23 de agosto de 2015.
Mohapatra, S; Rath, NM; Agrawal, A; Verma, J (octubre de 2013). «OPIPRAMOL: A NOVEL DRUG»(PDF). Delhi Psychiatry Journal16 (2): 409-411. Archivado desde el original el 11 de julio de 2020. Consultado el 15 de agosto de 2015.
«Anxiolytic (tranquilizer)». Memidex (WordNet) Dictionary/Thesaurus. Archivado desde el original el 16 de noviembre de 2018. Consultado el 2 de diciembre de 2010.
Krause W, Schutt B, Duka T (mayo de 1990). «Pharmacokinetics and acute toleration of the beta-carboline derivative abecarnil in man». Arzneimittelforschung40 (5): 529-32. PMID1974428.
Pöldinger W (1975). «Clinical trial of 3-methyl-5-(beta-N'-(N-m-chlorophenylpiperazino)ethyl)-pyrazole dihydrochloride (Mepiprazol) in the therapy of psychovegetative disorders». International Pharmacopsychiatry10 (1): 1-8. PMID1095510.
De Buck R, Van Durme R, Pelc I (mayo de 1975). «[A controlled double-blind crossover study of the efficacy of mepiprazol (EMD 16.923) and of diazepam in the treatment of neurotic disorders]». Acta Psychiatrica Belgica(en francés)75 (3): 320-33. PMID769484.
Saldaña Hernández OH, Hernández González J (1976). «[Psychopharmological research with EMD 16-923 in patients with different degrees of anxiety]». Neurología, Neurocirugía, Psiquiatría17 (1): 29-33. PMID1052713.
Maj J, Sypniewska M (1980). «Central action of mepiprazole». Polish Journal of Pharmacology and Pharmacy32 (4): 475-84. PMID7255266.
Fuxe K, Agnati LF, Ungerstedt U (enero de 1976). «The effect of mepiprazole on central monoamine neurons. Evidence for increased 5-hydroxytryptamine and dopamine receptor activity». European Journal of Pharmacology35 (1): 93-108. PMID943291. doi:10.1016/0014-2999(76)90304-6.
de Boer, Th. (1996). «The pharmacologic profile of mirtazapine». Journal of Clinical Psychiatry57 (4 Supp 1): 19-25. PMID8636062.
Müller WE, Siebert B, Holoubek G, Gentsch C (noviembre de 2004). «Neuropharmacology of the anxiolytic drug opipramol, a sigma site ligand». Pharmacopsychiatry37 (Suppl 3): S189-197. PMID15547785. doi:10.1055/s-2004-832677.
Defrance, R; Marey, C; Kamoun, A (1988). «Antidepressant and anxiolytic activities of tianeptine: an overview of clinical trials». Clinical Neuropharmacology. 11 Suppl 2: S74-82. PMID2902922.
Schruers, K; Griez, E (diciembre de 2004). «The effects of tianeptine or paroxetine on 35% CO2 provoked panic in panic disorder». Journal of Psychopharmacology18 (4): 553-8. PMID15582922. doi:10.1177/0269881104047283.
Uzbay, TI (mayo de 2008). «Tianeptine: potential influences on neuroplasticity and novel pharmacological effects». Progress in Neuro-psychopharmacology & Biological Psychiatry32 (4): 915-24. PMID17826881. doi:10.1016/j.pnpbp.2007.08.007.
Millan MJ, Brocco M, Gobert A, Dekeyne A (febrero de 2005). «Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade». Psychopharmacology (Berl.)177 (4): 448-58. PMID15289999. doi:10.1007/s00213-004-1962-z.
De Berardis et al. (2013). «Is there a role for agomelatine in the treatment of anxiety disorders? a review of published data». International Journal of Immunopathology and Pharmacology26 (2): 299-304. PMID23755745.
De Berardis, D; Serroni, N; Campanella, D; Olivieri, L; Moschetta, FS; Conti, CM; Conti, P; Di Giannantonio, M (abril de 2012). «A case of obsessive-compulsive disorder successfully treated with agomelatine monotherapy». Journal of Clinical Psychopharmacology32 (2): 289-290. PMID22388158. doi:10.1097/JCP.0b013e318249298c.
Bhutada, P; Dixit, P; Thakur, K; Deshmukh, P; Kaulaskar, S (julio de 2013). «Effects of agomelatine in a murine model of obsessive–compulsive disorder: Interaction with meta-chlorophenylpiperazine, bicuculline, and diazepam». The Kaohsiung Journal of Medical Sciences29 (7): 362-367. PMID23768699. doi:10.1016/j.kjms.2012.11.003.
Crippa, JA; Hallak, JE; Zuardi, AW; Chagas, MH; Quevedo, J; Nardi, AE (octubre de 2010). «Agomelatine in the treatment of social anxiety disorder». Progress in Neuro-Psychopharmacology and Biological Psychiatry34 (7): 1357-1358. PMID20637821. doi:10.1016/j.pnpbp.2010.07.007.
Gommoll C. et al. (agosto de 2015). «Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study». Int Clin Psychopharmacol. PMID26291335.
van der Kolk, BA (septiembre–octubre de 1987). «The drug treatment of post-traumatic stress disorder.». Journal of Affective Disorders13 (2): 203-13. PMID2960712. doi:10.1016/0165-0327(87)90024-3.
Southwick, SM; Bremner, JD; Rasmusson, A; Morgan CA, 3rd; Arnsten, A; Charney, DS (noviembre de 1999). «Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder.». Biological Psychiatry46 (9): 1192-204. PMID10560025. doi:10.1016/S0006-3223(99)00219-X.
Strawn, JR; Geracioti, TD, Jr (2008). «Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder.». Depression and Anxiety25 (3): 260-71. PMID17354267. doi:10.1002/da.20292.
Boehnlein, JK; Kinzie, JD (marzo de 2007). «Pharmacologic reduction of CNS noradrenergic activity in PTSD: the case for clonidine and prazosin.». Journal of Psychiatric Practice13 (2): 72-8. PMID17414682. doi:10.1097/01.pra.0000265763.79753.c1.
Najjar, F; Weller, RA; Weisbrot, J; Weller, EB (abril de 2008). «Post-traumatic stress disorder and its treatment in children and adolescents.». Current Psychiatry Reports10 (2): 104-8. PMID18474199. doi:10.1007/s11920-008-0019-0.
Kaminer, D.; Seedat, S. & Stein, D. (2005), «Post-traumatic stress disorder in children», World Psychiatry4 (2): 121-5, PMC1414752, PMID16633528..
Neylan,, T.; Lenoci, M. & Samuelson, K. (2006), «No Improvement of Posttraumatic Stress Disorder Symptoms With Guanfacine Treatment», American Journal of Psychiatry163 (12): 2186-2188, PMID17151174, doi:10.1176/appi.ajp.163.12.2186.
Kennett GA, Dourish CT, Curzon G (1987). «Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression». Eur J Pharmacol.134 (3): 265-74. PMID2883013. doi:10.1016/0014-2999(87)90357-8.
de Wit H, Vicini L, Haig GM, Hunt T, Feltner D. (junio de 2006). «Evaluation of the abuse potential of pagoclone, a partial GABAA agonist». Journal of Clinical Psychopharmacology26 (3): 268-73. PMID16702891.
Blanchard JC; Julou L. (marzo de 1983). «Suriclone: a new cyclopyrrolone derivative recognizing receptors labeled by benzodiazepines in rat hippocampus and cerebellum.». J Neurochem.40 (3): 601-7. PMID6298365. doi:10.1111/j.1471-4159.1983.tb08023.x.
Bandelow, B.; Wedekind, D.; León, T. (Jul 2007). «Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention». Expert Rev Neurother7 (7): 769-81. PMID17610384. doi:10.1586/14737175.7.7.769.
Owen, RT. (Sep 2007). «Pregabalin: its efficacy, safety and tolerability profile in generalized anxiety». Drugs Today (Barc)43 (9): 601-10. PMID17940637. doi:10.1358/dot.2007.43.9.1133188.
Goldstein, BJ; Weer, DM (mayo–Jun 1970). «Comparative evaluation of benzoctamine and diazepam in treatment of anxiety.». The Journal of clinical pharmacology and the journal of new drugs10 (3): 194-8. PMID4392683.
Ren, Jintao; Xiaobai Li; Xinxin Zhang; Min Li; Yan Wang; Yuchao Ma (julio de 2013). «The effects of intra-hippocampal microinfusion of d-cycloserine on fear extinction, and the expression of NMDA receptor subunit NR2B and neurogenesis in the hippocampus in rats». Progress In Neuro-Psychopharmacology And Biological Psychiatry44: 257-264. PMID23523746. doi:10.1016/j.pnpbp.2013.02.017.
Baker, Kathryn; Gavan P. McNally; Rick Richardson (octubre de 2012). «D-cycloserine does not facilitate fear extinction by reducing conditioned stimulus processing or promoting conditioned inhibition to contextual cues». Learning & Memory19 (10): 461-469. PMID22984284. doi:10.1101/lm.026674.112.
Neznamov, GG; Siuniakov, SA; Chumakov, DV; Bochkarev, VK; Seredenin, SB (2001). «Clinical study of the selective anxiolytic agent afobazol». Eksperimental'naia i klinicheskaia farmakologiia64 (2): 15-9. PMID11548440.
Silkina, IV; Gan'shina, TC; Seredin, SB; Mirzoian, RS (2005). «Gabaergic mechanism of cerebrovascular and neuroprotective effects of afobazole and picamilon». Eksperimental'naia i klinicheskaia farmakologiia68 (1): 20-4. PMID15786959.
Seredin, SB; Melkumian, DS; Val'dman, EA; Iarkova, MA; Seredina, TC; Voronin, MV; Lapitskaia, AS (2006). «Effects of afobazole on the BDNF content in brain structures of inbred mice with different phenotypes of emotional stress reaction». Eksperimental'naia i klinicheskaia farmakologiia69 (3): 3-6. PMID16878488.
Antipova, TA; Sapozhnikova, DS; Bakhtina, LIu; Seredenin, SB (2009). «Selective anxiolytic afobazole increases the content of BDNF and NGF in cultured hippocampal HT-22 line neurons». Eksperimental'naia i klinicheskaia farmakologiia72 (1): 12-4. PMID19334503.
Seredenin, SB; Antipova, TA; Voronin, MV; Kurchashova, SY; Kuimov, AN (2009). «Interaction of afobazole with sigma1-receptors». Bulletin of experimental biology and medicine148 (1): 42-4. PMID19902093. doi:10.1007/s10517-009-0624-x.
Medvedev, VE; Trosnova, AP; Dobrovol'skiĭ, AV (2007). «Psychopharmacotherapy of anxiety disorders in patients with cardio-vascular diseases: the use of aphobazole». Zh Nevrol Psikhiatr Im S S Korsakova.107 (7): 25-9. PMID18379478.
Val'Dman, AV; Zaikonnikova, IV; Kozlovskaia, MM; Zimakova, IE (1980). «Characteristics of the psychotropic spectrum of action of mebicar». Biulleten' eksperimental'noi biologii i meditsiny89 (5): 568-70. PMID6104993.
Mkrtchian, VR; Kozhokova, LZ (2012). «Adaptol--verges of possible». Likars'ka sprava / Ministerstvo okhorony zdorov'ia Ukrainy (5): 125-33. PMID23534281.
Malykh AG; Sadaie MR (Feb 2010). «Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.». Drugs.70 (3): 287-312. PMID20166767. doi:10.2165/11319230-000000000-00000.
Kumar V et al. (abril de 2000). «Anxiolytic activity of Indian Abies pindrow Royle leaves in rodents: an experimental study». Indian J Exp Biol.38 (4): 343-6. PMID11218810.
Sarris J et al. (2012). «Complementary medicine, exercise, meditation, diet, and lifestyle modification for anxiety disorders: a review of current evidence». Evid Based Complement Alternat Med. PMID22969831. doi:10.1155/2012/809653.
A. Moussaieff et al. (2008). «Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain». The Journal of The Federation of American Societies for Experimental Biology22 (8): 3024-3034. PMID18492727. doi:10.1096/fj.07-101865.
Koulivand, PH; Khaleghi, Ghadiri M; Gorji, A (2013). «Lavender and the nervous system». Evidence-based complementary and alternative medicine: eCAM.2013: 681304. PMID23573142. doi:10.1155/2013/681304.
Max H Pittler, Edzard Ernst (2003). «Kava extract versus placebo for treating anxiety». Cochrane Database Syst Rev. PMID12535473. doi:10.1002/14651858.CD003383.
Schmitz M, Jäckel M (1998). «[Comparative study for assessing quality of life of patients with exogenous sleep disorders (temporary sleep onset and sleep interruption disorders) treated with a hops-valarian preparation and a benzodiazepine drug]». Wien Med Wochenschr(en alemán)148 (13): 291-8. PMID9757514.
Birgit M. Dietz et al. (agosto de 2005). «Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro». Molecular Brain Research138 (2): 191-197. PMID15921820.
Shephard RA (junio de 1987). «Behavioral effects of GABA agonists in relation to anxiety and benzodiazepine action». Life Sci.40 (25): 2429-36. PMID2884549. doi:10.1016/0024-3205(87)90758-2.
Rothschild, A. M. (1966). «Histamine release by basic compounds». Handbook of Experimental Pharmacology(en inglés) (Berlín: Rocha e Silva, M.) 18: 386-430. Consultado el 28 de octubre de 2012.
María Del Pilar Rayón Iglesias (1997). «Utilización De Hipnóticos en España». Facultad de Farmacia. Departamento de farmacología. Universidad Complutense de Madrid. Consultado el 29 de julio de 2015.
«Anxiolytic (tranquilizer)». Memidex (WordNet) Dictionary/Thesaurus. Archivado desde el original el 16 de noviembre de 2018. Consultado el 2 de diciembre de 2010.
Mohapatra, S; Rath, NM; Agrawal, A; Verma, J (octubre de 2013). «OPIPRAMOL: A NOVEL DRUG»(PDF). Delhi Psychiatry Journal16 (2): 409-411. Archivado desde el original el 11 de julio de 2020. Consultado el 15 de agosto de 2015.
Kokila, K. (2013). «Copia archivada». Int J Pharm Pharm Sci,. 5 Suppl. 3: 70-73. Archivado desde el original el 24 de septiembre de 2015. Consultado el 23 de agosto de 2015.
Barlow, David H. Durand, V. Mark (2009). «Chapter 7: Mood Disorders and Suicide». Abnormal Psychology: An Integrative Approach (Fifth edición). Belmont, CA: Wadsworth Cengage Learning. p. 239. ISBN0-495-09556-7. OCLC192055408.